This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Biotech Stocks to Buy on First Vaccine Approval Optimism
by Zacks Equity Research
Here we discuss three potential stocks that can gain following mass availability of vaccine. Vaccination may release pent-up demand across sectors. It will also help biotechs progress with their clinical studies without any disruption.
Rhythm (RYTM) Up on FDA Approval of Weight Management Drug
by Zacks Equity Research
Rhythm's (RYTM) stock gains as FDA approves its lead product candidate for chronic weight management.
Reata (RETA) Omaveloxolone Program Faces Delay on FDA Update
by Zacks Equity Research
Reata's (RETA) omaveloxolone development in Friedreich's Ataxia gets delayed further as FDA proposes additional exploratory analyses to support filing regulatory application for its approval.
Merck (MRK) to Buy OncoImmune, Add Late-Stage COVID-19 Treatment
by Zacks Equity Research
The acquisition of OncoImmune will boost Merck's (MRK) portfolio with CD24Fc, a candidate in phase III studies for the treatment of patients with severe and critical COVID-19.
Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (RGEN) Outperforming Other Medical Stocks This Year?
Zacks.com featured highlights include: BJ's Wholesale Club, Dollar General, Repligen Corp, Hologic and Parker-Hannifin
by Zacks Equity Research
Zacks.com featured highlights include: BJ's Wholesale Club, Dollar General, Repligen Corp, Hologic and Parker-Hannifin
Repligen (RGEN) Looks Good: Stock Adds 6.1% in Session
by Zacks Equity Research
Repligen (RGEN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
J&J (JNJ) Seeks Label Expansion of Darzalex Faspro Combination
by Zacks Equity Research
J&J (JNJ) files regulatory application in the United States and Europe seeking label expansion of Darzalex Faspro in combination with pomalidomide and dexamethasone for treating multiple myeloma.
5 Top Stocks to Buy on Earnings Beat Potential
by Sanghamitra Saha
These top-ranked stocks are likely to beat on bottom line in their next releases.
AstraZeneca's (AZN) Asthma Drug Meets Primary Goal in Phase III
by Zacks Equity Research
AstraZeneca's (AZN) pipeline candidate tezepelumab achieves the primary goal in phase III NAVIGATOR study for addressing patients with severe, uncontrolled asthma.
Arena (ARNA) Q3 Earnings Top, Stock Down on Eczema Study Data
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) beats bottom-line estimates for third-quarter 2020. Mid-stage atopic dermatitis study on etrasimod fails to meet primary endpoint but phase III study may start soon.
Repligen (RGEN) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 42.86% and 8.75%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen (RGEN) Earnings Expected to Grow: What to Know Ahead of Q3 Release
by Zacks Equity Research
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Biotech Stocks to Buy Right Now Amid Coronavirus Woes
by Indrajit Bandyopadhyay
Here we discuss four biotech stocks, which hold solid potential even amid the coronavirus crisis that continues unabated.
Genocea to Initiate a Phase I/II Oncology Study on GEN-011
by Zacks Equity Research
Genocea's (GNCA) investigational new drug application to initiate a clinical study to evaluate its neoantigen-specific cell therapy candidate, GEN-011 in cancer patients gets FDA clearance.
Why Repligen Corporation (RGEN) Could Be an Impressive Growth Stock
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Repligen Corporation (RGEN).
Why Is Repligen (RGEN) Down 0.7% Since Last Earnings Report?
by Zacks Equity Research
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Axsome's NDA Filing for Migraine Candidate in Q4 on Track
by Zacks Equity Research
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-07, which is developed as an acute treatment of migraine. The company is on course to file the NDA in Q4.
Sorrento to Buy Privately-Held SmartPharm to Boost Pipeline
by Zacks Equity Research
Sorrento (SRNE) signs agreement to acquire SmartPharm Therapeutics in exchange for its common stock worth up to $19.4 million.
Looking for Earnings Beat? Buy These 5 Stocks With Potential
by Sanghamitra Saha
These top-ranked stocks are likely to beat on their bottom line in the next releases.
Albireo Down on Unimpressive Data From Mid-Stage NASH Study
by Zacks Equity Research
Albireo (ALBO) discontinues development of elobixibat in fatty liver diseases, following failure to achieve proof-of-concept for key NASH measures except LDL-C levels in a phase II study.
Eiger BioPharmaceuticals (EIGR) Catches Eye: Stock Jumps 8.6%
by Zacks Equity Research
Eiger BioPharmaceuticals (EIGR) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Top Ranked Momentum Stocks to Buy for August 13th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, August 13th.
Zacks.com featured highlights include: YETI, JD.com, Repligen, Shopify and Noble Energy
by Zacks Equity Research
Zacks.com featured highlights include: YETI, JD.com, Repligen, Shopify and Noble Energy